BioSpace News Archive

Celldex Therapeutics, Inc. announced that management will participate in fireside chats at the following investor conferences in November.

Agios Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization for PYRUKYND® for the treatment of PK deficiency in adult patients.

Chinook Therapeutics, Inc. provided a business update and reported financial results for the quarter and nine months ended September 30, 2022.

HilleVax, Inc. reported financial results for the quarter ended September 30, 2022, highlighted recent program progress, and outlined key upcoming milestones for HIL-214, the company’s investigational virus-like particle based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced financial results for the third quarter ended September 30, 2022.

Invivyd, Inc. announced financial results and business highlights for the third quarter ended September 30, 2022.

Viracta Therapeutics, Inc. reported financial results for the third quarter of 2022 and provided an update on recent corporate developments.

aTyr Pharma, Inc. announced third quarter 2022 results and provided a corporate update.

Bolt Biotherapeutics, Inc. reported financial results for the third quarter ended September 30, 2022 and provided a business update.

89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, reported its financial results for the third quarter ended September 30, 2022.